CHINA-FOREIGN ENTERPRISE-INVESTMENT-OPPORTUNITIES-BAYER

QIDONG, Dec. 2, 2020 -- A staff member observes the microscopic features of a product under research at a research and development center at Bayer HealthCare Company Limited Qidong Branch in Qidong, east China's Jiangsu Province, Dec. 2, 2020. The company has been introducing new pharmaceuticals to China and strengthened partnership with a number of academic institutes and business firms, including Tsinghua University and Peking University. It has also worked together with local agronomic and scientific institutes in providing Chinese farmers with better solutions, and helped advance green and sustainable development for the Chinese agriculture. The stable development of Chinese society guarantees Bayer's production and operation activities in China and has also increased Bayer's confidence and determination to invest in China. To address further demand of its drug products in China, Bayer kicked off the capacity expansion project of its Pharmaceuticals Product Supply Beijing site in August 2020. With an investment exceeding 60 million U.S. dollars, the planned project is expected to open at the end of 2022 and increase the estimated annual output of the Beijing site by around 40 percent, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. (Photo by Zhang Yuwei/Xinhua via Getty)